TOP TEN perturbations for 39032_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39032_at
Selected probe(set): 215111_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39032_at (215111_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

coronary artery disease study 2 / normal endothelial progenitor cell (133+) sample

Relative Expression (log2-ratio):4.1040945
Number of Samples:9 / 3
Experimental coronary artery disease study 2
133+ endothelial progenitor cells obtained from patients with coronary artery disease (CAD) prior to exercise. CAD patients were enrolled in a cardiac rehabilitation program. Medical management was stable for at least 1 month prior to program participation. Baseline testing was performed after an overnight fast (except for water).
Control normal endothelial progenitor cell (133+) sample
133+ endothelial progenitor cells obtained from healthy subjects.

A. fumigatus study 1 / uninfected immature dendritic cell sample

Relative Expression (log2-ratio):3.9627695
Number of Samples:2 / 2
Experimental A. fumigatus study 1
5 x 106 immature dendritic cells were cultivated together with 5 x 106 A. fumigatus germ tubes for 6h until isolation of total RNA.
Control uninfected immature dendritic cell sample
5 x 106 immature dendritic cells were cultivated without fungi.

cell cycle inhibition study 1 / untreated A2780 ovarian carcinoma cell sample

Relative Expression (log2-ratio):-3.9534836
Number of Samples:3 / 3
Experimental cell cycle inhibition study 1
Human ovarian carcinoma cells (A2780) exposed to 3 micromolar of a cell cycle inhibitor for 6hrs.
Control untreated A2780 ovarian carcinoma cell sample
Untreated human ovarian carcinoma cells (A2780).

R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-3.9154854
Number of Samples:2 / 4
Experimental R547 study 1 (24h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)

Relative Expression (log2-ratio):3.5359707
Number of Samples:2 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, clear cell sarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.

R547 study 1 (6h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-3.4999847
Number of Samples:4 / 4
Experimental R547 study 1 (6h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours.

actinomycin D study 1 / mannitol treated A549 cell sample

Relative Expression (log2-ratio):-3.3316784
Number of Samples:3 / 3
Experimental actinomycin D study 1
A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, actinomycin D (5 ug/mL final concentration) was added to the culture. ATC code:
Control mannitol treated A549 cell sample
A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, mannitol (5% final concentration) was added to the culture.

echinomycin study 1 / deferoxamine study 5

Relative Expression (log2-ratio):-3.2539797
Number of Samples:3 / 3
Experimental echinomycin study 1
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:---
Control deferoxamine study 5
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:

rosiglitazone study 5 (late) / IL-4; GM-CSF study 1 (late)

Relative Expression (log2-ratio):3.1119976
Number of Samples:6 / 6
Experimental rosiglitazone study 5 (late)
Monocytes, cultured with 2.5 uM rosiglitazone (RSG) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3. ATC code:
Control IL-4; GM-CSF study 1 (late)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3.

rosiglitazone study 4 / vehicle (DMSO/EtOH)/ IL-4/ GM-CSF treated monocyte sample

Relative Expression (log2-ratio):3.0664282
Number of Samples:3 / 3
Experimental rosiglitazone study 4
Monocytes were cultured for 5 days with 500 U/ml IL-4 and 800 U/ml GM-CSF, cytokine treatment was repeated at day 3. Rosiglitazone (RSG; 2.5 uM) was added at the beginning of differentiation. ATC code:
Control vehicle (DMSO/EtOH)/ IL-4/ GM-CSF treated monocyte sample
Monocytes were cultured for 5 days with 500 U/ml IL-4 and 800 U/ml GM-CSF, cytokine treatment was repeated at day 3. Vehicle (DMSO/ethanol) was added at the beginning of differentiation.